Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce the successful presentation of new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, USA (November 4-5, 2025).
The presentation generated exceptional interest from both the scientific and industry communities, with attendees continuing discussions around Defence's poster long after the official session concluded. The results presented by Dr. Maxime Parisotto, Chief Scientific Officer of Defence Therapeutics, demonstrated how Accum® enhances intracellular delivery and payload release, thereby amplifying the potency and therapeutic index of ADCs.
"The response to our new data was phenomenal," said Dr. Parisotto. "It's clear that the Accum® platform addresses one of the key challenges in ADC design-efficient endosomal escape and payload delivery. We are now moving forward to test Accum® across a broader range of on-market and development-stage ADCs to fully explore its potential to improve efficacy and patient outcomes."
The Company is now expanding its collaborative and internal testing programs to include multiple commercial and clinical-stage ADC constructs, aiming to validate Accum® as a plug-and-play enhancer for the next generation of targeted cancer therapies.
"Our goal is to demonstrate that Accum® can universally enhance the performance of ADCs, regardless of the payload or antibody used," said Dr. Mark Lambermon, Head of Quality and Operation at Defence Therapeutics, who was also in attendance in San Diego. "We are engaging with leading industry partners to accelerate these evaluations and bring this transformative technology closer to patients."
The Defence team extends its gratitude to the organizers of the World ADC Conference and to the many collaborators and industry partners who joined discussions in San Diego.
For partnership inquiries or to learn more about Defence's expanding ADC development initiatives, please contact:
info@defencetherapeutics.com
www.defencetherapeutics.com
About Defence:
Defence Therapeutics is a publicly-traded biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273393
SOURCE: Defence Therapeutics Inc.
